Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17077055 | 0.84 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL343558 | 0.84 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL9899781 | 0.82 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL342668 | 0.81 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL344058 | 0.81 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15322131 | 0.79 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10318609 | 0.79 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2771161 | 0.79 | ALDH1A1 (0.49) | OPRM1 | |
| SCHEMBL29222886 | 0.78 | OPRM1 (0.63) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1201 | 0.78 | OPRM1 (0.43) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | OPRM1 1387/4885OPRD1 1402/4885OPRK1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.